SynthesisArthritis research & therapy2018
Comorbidities in polymyalgia rheumatica: a systematic review.
Synthesis in Arthritis research & therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica.Annals of the rheumatic diseases · 2024Pooled it
- Article
- Lifetime risk of malignancy in polymyalgia rheumatica: a population-based matched cohort study from southern Norway.Rheumatology (Oxford, England) · 2026Article
- Frailty phenotypes and determinants of glucocorticoid-related adverse events in polymyalgia rheumatica at 12 months: a real-life single-center investigation.Clinical rheumatology · 2026Article
- Serum protein biomarkers for polymyalgia rheumatica: a case-control study.Frontiers in immunology · 2026Article
- MCCs in adults with autoimmune and inflammatory rheumatic diseases: evidence to date and future directions.Therapeutic advances in musculoskeletal disease · 2026Review
- Frequency, diagnosis, and management of polymyalgia rheumatica in Germany-database analysis of medical insurance data.Rheumatology (Oxford, England) · 2025Article
- Norwegian society of rheumatology recommendations on diagnosis and treatment of patients with Polymyalgia Rheumatica: a narrative review.BMC rheumatology · 2024Article
- [Polymyalgia rheumatica-A challenge in geriatrics : Interdisciplinary presentation of diagnostics and treatment].Zeitschrift fur Rheumatologie · 2024Article
- Autoimmune disease and the risk of anal cancer in the US population aged 66 years and over.Journal of the National Cancer Institute · 2024Article
- The contributions of deleterious rare alleles in NLRP12 and inflammasome-related genes to polymyalgia rheumatica.Scientific reports · 2024Article
- [Polymyalgia rheumatica-A challenge in geriatrics : Interdisciplinary presentation of diagnostics and treatment].Zeitschrift fur Gerontologie und Geriatrie · 2023Article
- Absence of Long-Lasting Morning Stiffness at the Time of Diagnosis as Paraneoplastic Warning in Patients with Polymyalgia Rheumatica (PMR): Data from Italian Single-Center Study.Life (Basel, Switzerland) · 2023Article
- An update on polymyalgia rheumatica.Journal of internal medicine · 2022Review
- Polymyalgia Rheumatica.Deutsches Arzteblatt international · 2022Review
- Fluorine-18 labeled fluorodeoxyglucose positron emission tomography/computed tomography used in diagnosing connective tissue diseases in fever of unknown origin/inflammatory of unknown origin patients.Clinical rheumatology · 2022Article
- What non-pharmacological treatments do people with polymyalgia rheumatica try: results from the PMR Cohort Study.Rheumatology international · 2022Observational
- Long-term use of glucocorticoids for polymyalgia rheumatica: follow-up of the PMR Cohort Study.Rheumatology advances in practice · 2022Article
- Systemic autoimmune disease as a cause of death: mortality burden and comorbidities.Rheumatology (Oxford, England) · 2021Article
- A pilot study of a nurse-led integrated care review (the INCLUDE review) for people with inflammatory rheumatological conditions in primary care: feasibility study findings.Pilot and feasibility studies · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
BACKGROUND AND
aimComorbidities are known to exist in many rheumatological conditions. Polymyalgia rheumatica (PMR) is a common inflammatory rheumatological condition affecting older people which, prior to effective treatment, causes severe disability. Our understanding of associated comorbidities in PMR is based only on case reports or series and small cohort studies. The objective of this study is to review systematically the existing literature on the comorbidities associated with PMR.
methodsMEDLINE, EMBASE, PsycINFO and CINAHL databases were searched for original observational research from inception to November 2016. Papers containing the words 'Polymyalgia Rheumatica' OR 'Giant Cell Arteritis' OR the terms 'PMR' OR 'GCA' were included. Article titles were reviewed based on pre-defined criteria by two reviewers. Following selection for inclusion, studies were quality assessed using the Newcastle-Ottawa tool and data were extracted.
resultsA total of 17,329 papers were reviewed and 41 were incorporated in this review, including three published after the search took place. Wide variations were found in study design, comorbidities reported and populations studied. Positive associations were found between PMR diagnosis and stroke, cardiovascular disease, peripheral arterial disease, diverticular disease and hypothyroidism. Two studies reported a positive association between PMR and overall malignancy rate. Seven studies reported an association between PMR and specific types of cancer, such as leukaemia, lymphoma, myeloproliferative disease and specified solid tumours, although nine studies found either no or negative association between cancer and PMR.
conclusionQuantification of the prevalence of comorbidities in PMR is important to accurately plan service provision and enable identification of cases of PMR which may be more difficult to treat. This review highlights that research into comorbidities in PMR is, overall, methodologically inadequate and does not comprehensively cover all comorbidities. Future studies should consider a range of comorbidities in patients with a validated diagnosis of PMR in representative populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.